These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 34185620)

  • 1. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
    Boucly A; Savale L; Jaïs X; Bauer F; Bergot E; Bertoletti L; Beurnier A; Bourdin A; Bouvaist H; Bulifon S; Chabanne C; Chaouat A; Cottin V; Dauphin C; Degano B; De Groote P; Favrolt N; Feng Y; Horeau-Langlard D; Jevnikar M; Jutant EM; Liang Z; Magro P; Mauran P; Moceri P; Mornex JF; Palat S; Parent F; Picard F; Pichon J; Poubeau P; Prévot G; Renard S; Reynaud-Gaubert M; Riou M; Roblot P; Sanchez O; Seferian A; Tromeur C; Weatherald J; Simonneau G; Montani D; Humbert M; Sitbon O
    Am J Respir Crit Care Med; 2021 Oct; 204(7):842-854. PubMed ID: 34185620
    [No Abstract]   [Full Text] [Related]  

  • 2. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monotherapy in patients with pulmonary arterial hypertension at four German PH centres.
    Stubbe B; Seyfarth HJ; Kleymann J; Halank M; Al Ghorani H; Obst A; Desole S; Ewert R; Opitz CF
    BMC Pulm Med; 2021 Apr; 21(1):130. PubMed ID: 33882879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
    Pestaña-Fernández M; Rubio-Rivas M; Tolosa-Vilella C; Guillén-Del-Castillo A; Freire M; Vargas-Hitos JA; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Espinosa G; Colunga-Argüelles D; Ortego-Centeno N; Trapiella-Martínez L; Carbonell-Muñoz C; Pla-Salas X; Perales-Fraile I; Corbella X; Fonollosa-Pla V; Simeón-Aznar CP;
    J Rheumatol; 2020 Jan; 47(1):89-98. PubMed ID: 30770503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges.
    Anderson J; Lavender M; Lau E; Celermajer D; Collins N; Dwyer N; Feenstra J; Horrigan M; Keating D; Keogh A; Kotlyar E; Ng B; Proudman S; Steele P; Thakkar V; Weintraub R; Whitford H; Williams T; Wrobel J; Strange G
    Heart Lung Circ; 2020 Oct; 29(10):1459-1468. PubMed ID: 32280014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.
    Deshwal H; Weinstein T; Salyer R; Thompson J; Cefali F; Fenton R; Bondarsky E; Sulica R
    Ther Adv Respir Dis; 2023; 17():17534666231199693. PubMed ID: 37795626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
    Gerhardt F; Fiessler E; Olsson KM; Kayser MZ; Kovacs G; Gall H; Ghofrani HA; Badr Eslam R; Lang IM; Benjamin N; Grünig E; Halank M; Lange TJ; Ulrich S; Leuchte H; Held M; Klose H; Ewert R; Wilkens H; Pizarro C; Skowasch D; Wissmüller M; Hellmich M; Olschewski H; Hoeper MM; Rosenkranz S
    Circulation; 2024 May; 149(20):1549-1564. PubMed ID: 38606558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension: A Retrospective Study.
    Khan NA; Khan RA; Tonelli AR; Highland KB; Chaisson NF; Jacob M; Renapurkar R; Dweik RA; Heresi GA
    Chest; 2019 Jul; 156(1):45-52. PubMed ID: 30776364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
    White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
    Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 12. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
    Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
    Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
    [No Abstract]   [Full Text] [Related]  

  • 13. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portopulmonary hypertension in the current era of pulmonary hypertension management.
    Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O
    J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
    Farber HW; Miller DP; Meltzer LA; McGoon MD
    J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand.
    Strange G; Lau EM; Giannoulatou E; Corrigan C; Kotlyar E; Kermeen F; Williams T; Celermajer DS; Dwyer N; Whitford H; Wrobel JP; Feenstra J; Lavender M; Whyte K; Collins N; Steele P; Proudman S; Thakkar V; Keating D; Keogh A;
    Heart Lung Circ; 2018 Nov; 27(11):1368-1375. PubMed ID: 29029950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension.
    Olsson KM; Richter MJ; Kamp JC; Gall H; Heine A; Ghofrani HA; Fuge J; Ewert R; Hoeper MM
    J Heart Lung Transplant; 2019 Jul; 38(7):748-756. PubMed ID: 31128966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.